JP2001145471A - Food material derived from purple sweet potato and having blood circulation-improving effect - Google Patents

Abstract

PROBLEM TO BE SOLVED: To obtain a blood circulation improver containing as active ingredient an aqueous solvent extract derived from purple sweet potatoes, and to obtain a food (material) containing an effective amount of the active ingredient. SOLUTION: The blood circulation improver and food (material) are obtained based on having found that purple sweet potatoes have the rat life-lengthening effect for rats under hypoxic conditions, cerebral blood flow (oxygen supply quantity)-increasing effect and blood vessel-relaxing effect as well as antioxidative ability having been known so far.

Description

DETAILED DESCRIPTION OF THE INVENTION

[0001]

[Field of the Invention]

2. Description of the Related Art Today, with the changes in economic conditions and dietary environment, the disease structure has changed drastically, infectious diseases frequently occurring in the age of malnutrition have decreased, cerebrovascular disorders, cancer, ischemic diseases, diabetes , Allergic diseases and the like are increasing. as a result,
The concept of “medical and dietary sources” has raised interest in preventing and ameliorating these diseases by dietary components, and has led to a health food boom. However, expectations for health foods are spreading not only to food manufacturers but also to peripheral industries such as pharmaceuticals and cosmetics.
Among them, the purchasing trend of health foods has shifted to “disease improvement type”, and themes are cancer, improvement of blood flow, and improvement of vision. Therefore, various functional food materials have been spotlighted.

[0002] One of them is purple potato. Research on high value-added by developing new uses of purple potatoes is being conducted at Kyushu Agricultural Experiment Station and other research institutions of the Ministry of Agriculture and Fisheries. As a result, purple potato has liver function improving effect, anti-mutagenicity, angiotensin I converting enzyme inhibitory activity (Masayoshi Yoshimoto, Osamu Yamakawa, Ikuo Suda, Food and Development. Kenko Sangyo Shimbun, 33: 15-17, 199
It has been revealed that it has physiological functions such as 8).
However, there has been no report on the blood circulation improving effect of the extract of purple potato.

[0003]

DISCLOSURE OF THE INVENTION The present invention relates to an aqueous solvent extract derived from purple potato, a blood circulation improving agent containing the extract as an active ingredient, and an effect of the extract for producing a food for improving blood circulation. It is an object to use a quantity and to provide a food containing an effective amount of the extract.

[0004]

Means for Solving the Problems The present inventors have conducted various studies in order to solve the above-mentioned problems, and as a result, it has been found that, in addition to the antioxidant ability known so far, the survival of rats under hypoxia was improved. We found that it had an effect, tried to elucidate its mechanism of action, and confirmed that cerebral blood flow increased due to vasorelaxation. In other words, it has been clarified that the cerebral blood flow rate increases under hypoxia, and that the life extension effect is exhibited by increasing the oxygen supply amount and the glucose supply amount to the brain, thereby completing the present invention.

That is, the present invention provides (1) a blood circulation improving agent containing an aqueous solvent extract derived from purple potato as an active ingredient, (2) a brain metabolic function improving agent containing the above extract as an active ingredient, 3) The extract of (1) in which the aqueous solvent is water or hydroalcohol, (4) the extract of (3) in which water or hydroalcohol is weakly acidic with a pH of about 5 or less, and (5) the blood circulation. Use of an effective amount of the extract of (1) for producing a food having an improving function, (6) Use of an effective amount of the extract of (1) for producing a food having a function of improving brain metabolism. Use, (7) the food is a health food, a functional food, or a food for specified health use (5) or (6)
Use of the extract of (8), a food for improving blood circulation containing an effective amount of the extract of (1), (9) a food for improving brain metabolism containing an effective amount of the extract of (1), and ( 10) The food of (8) or (9), which is a health food, a functional food, or a food for specified health use.

[0006]

BEST MODE FOR CARRYING OUT THE INVENTION The raw purple potato used as a raw material in the present invention includes, for example, Ayamurasaki, Yamakawa purple, Tanegashima native, Ei purple, Chiran purple, Nakamurasaki, etc. Among them, Ayamurasaki is preferred. Ayamurasaki is a breed obtained by crossing the native species Yamakawa purple with Chiran-kei and selecting Kyushu 109, and crossing Kyushu 109 with low-sugar high-yield Satsuma Hikari, which was registered in Agriculture and Forestry in 1995 (Yoshimoto). Makoto, Osamu Yamakawa, Ikuo Suda: Food and Development. 33 (8): 15-17, 1998).

[0007] These purple potatoes are used to improve the extraction efficiency of raw or frozen potatoes.
Cut into small pieces or powder. The extract of purple potatoes of the present invention can be obtained using water extraction, aqueous solvent extraction, supercritical extraction, micellar extraction and the like. The case of using water extraction or aqueous solvent extraction will be described. Water or aqueous alcohol is used as the extraction solvent. Examples of the alcohol include methanol, ethanol, and propanol, and among them, ethanol is preferable. When aqueous alcohol is used, the mixing ratio of water and alcohol is not particularly limited, but the alcohol is preferably 30 to 70% by weight. The pH of the aqueous solvent may be neutral, but is preferably set to a weakly acidic pH of about 5 or less. More preferably, the pH is 4 to 3. pH adjusters are known and include, for example, organic acids such as citric acid, tartaric acid and malic acid, and inorganic acids such as hydrochloric acid, sulfuric acid and phosphoric acid. The amount of the solvent is 2 to 20 parts by weight, preferably 5 to 10 parts by weight, based on 1 part by weight of the extraction raw material. The extraction temperature may be room temperature, but it is heated to increase the extraction efficiency. In that case, the temperature is set lower than the temperature (64 ° C.) at which the starch gelatinizes. Preferably 50 to
60 ° C. The extraction time is approximately one day and night at room temperature, and 2 to 10 hours when heated.

After stopping the extraction operation, the residue is removed,
Collect the extract. For the removal of the residue, known solid-liquid separation means such as filtration and centrifugation are appropriately used in combination. The extract can be used as it is as an additive to the functional food material, but when aqueous alcohol is used as the extraction solvent, it is desirable to distill off the alcohol portion. The extract may be concentrated or dried to a soft extract or a dry powder. These series of operations are known (for example, Ryo Fuka,
Toshiyuki Uesugi, “Development of Pharmaceuticals 11”, edited by Yoshinobu Nakai, p287-310,
Hirokawa Shoten, 1989; Yoshimasa Ichio “Development of Continued Pharmaceuticals 15”,
Harada Masatoshi, ed., P123-146, Hirokawa Shoten, 1992), and those skilled in the art can appropriately modify these known techniques to obtain soft extracts and dry powders.

Further, using an adsorbing resin or a membrane,
Proteins, carbohydrates, lipids and the like in the extract may be removed. As the adsorption resin, a nonpolar porous polymer resin is preferable, and a column filled with the resin is used. Examples of the resin include a styrene-based resin and an acrylic acid-based resin,
For example, HP-20, HP-50, SP-206, SP-8
25 (manufactured by Mitsubishi Chemical Corporation) and Amberlite XAD
-4 (manufactured by Organic Chemical Industry Co., Ltd.) or the like can be used. The liquid is passed, for example, in the range of SV = 1 to 10.

[0010] The extract of the present invention thus obtained includes an extract as it is (may contain a residue), a concentrate thereof, an extract, a paste, a dry powder and the like.
The extract of the present invention has physiological activities such as promotion of blood circulation and increase in oxygen supply, as shown in Test Examples described later.
As a result, an effect of improving brain metabolic function can be expected.

When the extract of the present invention (in the case of an extract) is orally administered as a blood circulation improving agent,
50 to 2000 mg per day as solid content of extract
Administer the equivalent. Here, the solid content of the extract refers to the residue after evaporating the solvent of the extract. The extract may be used alone or in combination with a food-hygienically acceptable compound to be processed into a dietary supplement, a health food, a functional food, or a food for specified health use. For example, compounds such as stabilizers, preservatives, coloring agents, and flavoring vitamins are appropriately added to the above extract and mixed, and tablets (tablets), granules, granules, powders, capsules, Liquid,
It can be used in a form suitable for foods such as creams and beverages.

Furthermore, food materials, such as royal jelly, chlorella, spirulina, ginseng, nucleic acid, reishi, agaricus prasei muril, maitake, mycelium (corticides, etc.), chitin chitosan, lecithin, aloe, ginkgo When used in combination with leaves, turmeric, blueberries, saw palmetto, soy isoflavones, red yeast rice, etc., a synergistic or additive effect of the extract of the present invention which is further added to the original physiological action of these materials can be expected. The purple potato, which is a raw material of the extract of the present invention, has already been used as a food for a long time, and there is no problem in terms of safety as a raw material. The extract can also be used as a safe functional food as a result of the toxicity test.

[0013]

EXAMPLES Hereinafter, the present invention will be described specifically with reference to test examples, but the present invention is not limited to these specific examples. The extract used in the following test examples was an extract extracted from Ayamurasaki (Nichino Chemical Co., Ltd., lot.9041).
4).

Test Example 1 Toxicity test for repeated oral administration Ayamurasaki extract (hereinafter referred to as “extract”) was administered to Crj: CD (SD) IGS rats (male 4 weeks old) once daily at a maximum of 800 mg / kg. And gavage administration for 3 consecutive weeks.
As a result, no toxicological abnormalities were observed in general symptoms, body weight, food consumption, water consumption, organ weight, blood cells, blood biochemical tests, and organ pathological findings.

Test Example 2 Life Prolonging Effect Under Hypoxic Conditions The brain is a tissue with a very high metabolic activity, and is said to consume 20% of the oxygen consumption of a living body. Cerebral hemorrhage, ischemic state due to cerebral infarction, etc. is induced, and the brain falls into a hypoxic state,
Its metabolic function declines rapidly, making it difficult to maintain vital phenomena. In other words, the supply of oxygen to the brain is indispensable for sustaining life and maintaining abilities such as thinking, which are important for "human beings". In order to evaluate the enhancement of cerebral metabolic function of ginkgo biloba leaf extract, a report examining the effect of prolonging survival time under hypoxic conditions (L. Karcher et.al., Naunyn-Schmiedeber
g's Arch Pharmacol. 327: 31-35, 1984). According to this report, the effect of improving the metabolic function of the extract on the brain was evaluated by the following administration routes.

1) Intraperitoneal administration SDIGS rats (male, 8 weeks old) were divided into groups based on body weight (8 rats per group). The extract was dissolved in distilled water for injection, and then extracted as 10.5 mg / kg, 52.5 mg / kg,
105 mg / kg and 210 mg / kg were administered intraperitoneally. The control group received intraperitoneal distilled water for injection. The administration volume of the test group and the control group was 10 ml / kg. At 30 minutes after the intraperitoneal administration, two mice were sequentially placed in a vacuum desiccator to reduce the pressure (180 mmHg). The determination of the survival time was defined as the time from the point at which 180 mmHg was reached to the point at which respiration was stopped. The respiratory arrest was determined by observing the appearance. For statistical processing, a control group and a test group were simultaneously compared by Dunnett's multiple comparison. The results are shown in FIG. From FIG. 1, it is apparent that the extract has a life-prolonging effect effect in a dose-dependent manner. It is known that a living body responds to maintaining the brain function most in an emergency for maintaining life. The extract of the present invention, under oxygen deficiency,
The present study revealed that the compound has an extremely excellent effect on maintaining brain function.

2) Oral administration The intraperitoneal administration of the extract has revealed that the extract of the present invention has the effect of increasing the oxygen supply to the brain. This is important when developing the extract as a functional food material. Therefore, the following experiment was performed. SDIGS rats (male 7
Weeks) were grouped based on body weight (5 animals per group). Fasted overnight the day before the test. After the extract is dissolved in distilled water for injection,
210 mg / 10 ml / kg was orally administered. The control group was orally administered distilled water for injection. The administration volume of the test group and the control group was 10 ml / kg. When 50 minutes had passed after oral administration, two animals were placed in a vacuum desiccator sequentially and the pressure was reduced (180 mmHg). The determination of the survival time was the same as in Test Example 1. The results are shown in FIG. From FIG. 2, it is clear that oral administration of the extract has a prolonged life under hypoxia similarly to intraperitoneal administration. The active ingredients of this extract are currently not clear, but at least the ingredients that show efficacy are
This indicates that absorption from the digestive tract is sufficient. That is, the extract of the present invention is useful as a functional food material. The shorter survival time in the control group compared to the intraperitoneal test is considered to be due to the effect of fasting and the age of the rats.

[Test Example 3] Increase in cerebral blood flow When considering the effect of prolonging life under hypoxia, one of the factors may be to promote the supply of oxygen and glucose as an energy source to brain tissue. . Thus, the effect on cerebral blood flow was evaluated. SDIGS rats (male 6 ~
7 weeks old) was used. Three control groups and 11 test groups were used. Fasted overnight the day before the test. Urethane anesthesia (1.4g / kg
ip) rats into polyethylene tubing (0.7 mm id)
6 mm, outer diameter 1.22 mm) was inserted from the mouth until it reached the fundus. While the scalp was incised and cooled with cooling physiological saline, the parietal bone was peeled off with a mini drill (Nippon Riken Kikai Co., Ltd. “NRK Minitar M-11-BS type”), and a small window of 3 to 4 mm square was opened. A blood flow measuring device ("LASERFLO BPM2") was set on the exposed dura. Observation was performed for 20 to 40 minutes until the blood flow was stabilized.
When blood flow stabilized, the extract was orally administered through a polyethylene tube. The extract was dissolved in distilled water for injection and administered at 210 mg / kg. For the control group, distilled water for injection was used. The administration volume was 5 ml / kg for both groups.
With the extract administration time set to 0 minute, the blood flow rate (the amount of blood flowing per minute per 100 g tissue) was measured for 60 minutes. The results are shown in FIG. FIG. 3 shows a representative example.
In the control group, there was no change in blood flow over time (FIG. 3
(1)) In the group to which the extract was orally administered, the blood flow gradually increased from around 30 minutes after administration (FIG. 3 (2)), around 30 minutes and 5 minutes.
Example in which blood flow increases around 0 to 60 minutes (FIG. 3)
(3)), several patterns were observed, such as an example in which the blood flow increased around 50 to 60 minutes (FIG. 3 (4)). It is considered that the time during which the blood flow increases is closely related to the pharmacokinetics of the extract. In any case, these results indicate that oral administration of the extract has the effect of increasing cerebral blood flow and consequently increasing oxygen supply and improving cerebral metabolic function. It is shown.

[Test Example 4] Increase of auricular blood flow The effect of improving peripheral blood flow was examined using three SDIGS rats (male, 7 weeks old). Urethane anesthesia (1.4 g / kg i.
p) A blood flow measuring device ("LASERFLO BPM2") was set on the pinna of the rat. After observing for 20 to 40 minutes to confirm that the blood flow rate was stable, the extract was administered intraperitoneally. After the extract was dissolved in distilled water for injection, 20 mg / kg was administered. For the control group, distilled water for injection was used. The administration volume of the test group and the control group is 1
It was 0 ml / kg. Blood flow (100
The amount of blood flowing per minute per g tissue) was measured. Representative results are shown in FIG.

From 15 minutes to 25 minutes after the administration of the extract, the blood flow at the pinna became maximum. It is considered that the reason why the blood flow increases earlier than in the oral administration (cerebral blood flow test) is due to the intraperitoneal administration and does not require absorption from the digestive tract. This indicates that the intraperitoneal administration of the extract has an effect of improving blood flow even in peripheral tissues, and it is expected that the extract of the present invention is effective for poor peripheral blood flow such as coldness and stiff shoulders.

[Test Example 5] Vasodilatory action The following test was conducted to examine the factors of the blood flow increasing action. SDIGS rats (male 8-9 weeks old) were used. After banging the occipital region of the rat, the animal was sacrificed by exsanguination, and the aorta was excised from the arch to the diaphragm. In a Krebs-Henseleit solution, fats and connective tissues attached to blood vessels were removed, cut in a spiral shape, and equally divided to prepare two blood vessel specimens. A 0.5 g load was applied to the specimen, and a Magnus tube filled with Krebs-Henseleit solution (10 m in length) aerated with 95% O 2 + 5% CO ₂ was used.
1, 37 ° C.) for 1 hour. After inducing contraction by phenylephrine (final concentration 1 × 10 ⁻⁷ M) which is an α agonist, the extract was added to a final concentration of 0.1 mg / ml and 0.3 mg.
/ Ml, 1.1 mg / ml, and 3.2 mg / ml. The change in relaxation was measured using a transducer. FIG. 5 shows the results.

From FIG. 5, it is clear that the extract of the present invention suppresses the contraction of blood vessels due to the α agonist. That is, the extract of the present invention has a vasorelaxant action, and this action is considered as one of the factors for increasing blood flow. In addition, it has been obtained that the vasorelaxation effect is dependent on endothelial cells. The above series of test results show that the aqueous solvent extract derived from the purple potato of the present invention has a cerebral function improving action based on physiological activities such as improvement of blood vessel function and increase in oxygen supply.

[0023]

Industrial Applicability The aqueous solvent extract derived from purple potato of the present invention has an excellent blood circulation improving effect. Therefore, by ingesting the extract, or a food containing the extract in a daily diet, blood circulation is improved, various diseases related to peripheral blood circulation failure, for example,
It is useful for prevention and improvement of coldness, numbness of limbs, diabetes, menopause, rheumatism, neuralgia, varicose veins, cerebral dysfunction, and the like.

[Brief description of the drawings]

BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1 is a graph showing the survival effect of rats under hypoxia after intraperitoneal administration of Ayamurasaki extract to rats. Ayamurasaki extract, 10.5 mg / kg, 52.5 mg / kg, 105 mg / kg, and 21 mg / kg for SDIGS rats (male, 8 weeks old)
After intraperitoneal administration of 0 mg / kg, put in a vacuum desiccator,
The time from the point of reaching 0 mmHg to the point of stopping breathing was measured. Bars indicate mean ± standard deviation. p <0.05
(*).

FIG. 2 is a graph showing the survival effect of rats under hypoxia after oral administration of Ayamurasaki extract to rats. SDIGS rats (male, 7 weeks old) were fasted overnight the day before the test. After oral administration of Ayamurasaki extract, 210 mg / kg, it was placed in a vacuum desiccator, and the time from the point of reaching 180 mmHg to the point of respiratory arrest was measured. Bars indicate mean ± standard deviation. p <0.01 (**).

FIG. 3 is a graph showing the effect of increasing the blood flow in the brain after oral administration of Ayamurasaki extract to rats. SDIGS rats (males 6-7 weeks old) fasted overnight the day before the test. Ayamurasaki extract was orally administered through a polyethylene tube (the extract administration time was set to 0 minute), and the blood flow on the dura of the brain (the amount of blood flowing per minute per 100 g of tissue) was continuously measured for 60 minutes.

FIG. 4 is a graph showing the effect of increasing auricular blood flow after intraperitoneal administration of Ayamurasaki extract to rats. A blood flow measuring device (LASERFLO BPM2) was set on the pinna of an SDIGS rat (male, 7 weeks old), and Ayamurasaki extract was intraperitoneally administered. The blood flow rate (the amount of blood flowing per minute per 100 g tissue) was measured for 60 minutes.

FIG. 5 is a view showing a blood vessel relaxing action. After inducing a contraction with phenylephrine (final concentration: 1 × 10 ⁻⁷ M) to an aortic vascular specimen of an SDIGS rat (male 8 to 9 weeks old), Ayamurasaki extract was cumulatively added. The change in relaxation of the aortic specimen in the Magnus tube was measured using a transducer.

──────────────────────────────────────────────────続 き Continued on the front page (51) Int.Cl. ⁷ Identification symbol FI Theme coat ゛ (Reference) A61P 25/28 A61P 25/28 F-term (Reference) 4B016 LC07 LG06 LP02 4B018 MD53 ME14 MF01 4C088 AB12 AC12 BA09 BA10 CA04 CA23 NA14 ZA15 ZA36

Claims (10)

[Claims] 1. A blood circulation improving agent comprising an aqueous solvent extract derived from purple potato as an active ingredient. 2. A cerebral metabolic function improving agent comprising the above extract as an active ingredient. 3. The extract according to claim 1, wherein the aqueous solvent is water or a hydroalcoholic. 4. The extract according to claim 3, wherein the water or the hydrous alcohol is weakly acidic with a pH of about 5 or less. 5. Use of an effective amount of the extract according to claim 1 for the production of a food product having the function of improving blood circulation. 6. Use of an effective amount of the extract according to claim 1, for the manufacture of a food having a function of improving brain metabolism. 7. The use of the extract according to claim 5, wherein the food is a health food, a functional food, or a food for specified health use. 8. A food for improving blood circulation, comprising an effective amount of the extract according to claim 1. A food for improving cerebral metabolism, comprising an effective amount of the extract according to claim 1. 10. The food according to claim 8, which is a health food, a functional food, or a food for specified health use.